ABEC Expands Process Sciences to Tackle Biopharma Bottlenecks

BETHLEHEM, PA – May 06, 2026 – As the biopharmaceutical industry races to develop next-generation therapies against a backdrop of rising costs and complexity, ABEC, a global leader in bioprocess engineering, has announced a significant expansion of its Process Sciences group. The initiative aims to directly address critical manufacturing hurdles by integrating advanced modeling, experimental validation, and custom equipment design to accelerate drug development timelines, mitigate risks, and enhance production yields.

The move comes at a crucial time. The bioprocess technology market is experiencing explosive growth, projected to swell from approximately $44 billion in 2026 to over $85 billion by 2031. This surge is fueled by the increasing dominance of biologics—such as monoclonal antibodies, vaccines, and cell therapies—which now constitute over 30% of new drug approvals. However, bringing these complex medicines from the lab to patients is fraught with challenges, from unpredictable scale-up issues to stringent regulatory oversight.

ABEC's expanded group is positioned to tackle these problems head-on, offering a holistic service that supports clients from early-stage development through full-scale commercial production. By combining deep engineering expertise with sophisticated digital tools, the company intends to provide a more predictable and efficient path to market.

The New Era of Integrated Process Optimization

At the heart of ABEC's strategy is a powerful synergy between computational modeling and real-world experimentation. The Process Sciences team utilizes a suite of advanced simulation tools, most notably Computational Fluid Dynamics (CFD), to create highly accurate digital twins of bioprocessing environments. This allows engineers to analyze and optimize critical parameters—such as mass transfer, agitation, blend times, and CO₂ stripping—in a virtual space before committing to costly and time-consuming physical runs.

This modeling-first approach significantly de-risks the notoriously difficult process of scaling up. For example, by using CFD to simulate fluid behavior inside a bioreactor, ABEC can predict and resolve potential issues like insufficient mixing or excessive shear stress on delicate cells, which can severely impact product quality and yield. In some cases, these simulations have been shown to cut critical metrics like blend time by as much as 50%, accelerating process development and improving efficiency.

These digital insights are then validated through hands-on experimentation in ABEC’s dedicated facilities. The company can conduct real-world mixing studies and live cell or microbial runs at scales ranging from 200mL laboratory setups to 6,000-liter commercial-scale systems. This multi-scale validation ensures that the optimized processes developed in simulations perform as expected in the physical world, providing a robust data package that supports Quality by Design (QbD) initiatives and smooths the path toward regulatory approval.

"Process Sciences gives our customers confidence as they move from development to production," said Scott Pickering in the company's announcement. "By combining modeling, experimental validation, and custom equipment design, we help optimize performance, improve yield, and reduce uncertainty."

De-Risking the Path from Lab to Market

The journey of a biologic drug is perilous, with scale-up and technology transfer representing two of the most significant failure points. A process that works perfectly in a 10-liter lab bioreactor can behave unpredictably in a 2,000-liter production vessel, leading to costly batch failures, project delays, and regulatory headaches. ABEC's expanded capabilities are designed to create a seamless bridge between these stages.

By deeply characterizing a process from its inception, the Process Sciences team helps biomanufacturers avoid common pitfalls. Their expertise spans both microbial fermentation and animal cell culture, allowing them to tailor solutions across a wide spectrum of biopharma applications. The detailed process understanding generated through their integrated approach provides a solid foundation for technology transfer, ensuring that a process can be reliably replicated at different sites or scales without compromising product quality or consistency.

This is particularly vital in today's highly regulated environment. Regulatory bodies like the FDA and EMA are increasingly emphasizing a scientific, risk-based approach to manufacturing. The data generated through CFD modeling and multi-scale experimental runs provides the concrete evidence needed to demonstrate process control and product quality, satisfying regulatory requirements and minimizing the risk of late-stage setbacks.

Customization as a Competitive Edge

While competitors like Sartorius and Merck KGaA offer their own comprehensive bioprocessing solutions, ABEC continues to differentiate itself through a core philosophy: designing equipment around the process, not forcing the process into standard equipment. This custom-engineering approach is a cornerstone of the Process Sciences group's value proposition.

Instead of providing one-size-fits-all hardware, ABEC collaborates with clients to design and build systems tailored to their unique process requirements. This bespoke strategy offers several key advantages. Custom-designed systems can be seamlessly integrated into existing facility layouts, feature optimized Clean-in-Place (CIP) and Sterilize-in-Place (SIP) cycles for faster changeovers, and incorporate hygienic designs that minimize contamination risk.

While custom solutions may involve a higher initial investment, they often result in significant long-term savings through improved productivity, higher yields, and greater operational efficiency. For many clients, a unique design created for a specific product can become their new internal standard, delivering cost and schedule benefits across their entire drug portfolio.

As the biopharmaceutical landscape becomes more competitive and the therapies more complex, the ability to fine-tune every aspect of production is no longer a luxury but a necessity. By expanding its Process Sciences group, ABEC is betting that this deeply integrated, highly customized, and science-led approach is the key to unlocking the next wave of biomanufacturing innovation and bringing life-saving therapies to patients more quickly and reliably.